PL2402002T3 - Kompozycje zawierające kwas 1,2,4-oksadiazolobenzoesowy i ich zastosowania do leczenia chorób związanych z przedwczesnym kodonem stop - Google Patents
Kompozycje zawierające kwas 1,2,4-oksadiazolobenzoesowy i ich zastosowania do leczenia chorób związanych z przedwczesnym kodonem stopInfo
- Publication number
- PL2402002T3 PL2402002T3 PL11175569T PL11175569T PL2402002T3 PL 2402002 T3 PL2402002 T3 PL 2402002T3 PL 11175569 T PL11175569 T PL 11175569T PL 11175569 T PL11175569 T PL 11175569T PL 2402002 T3 PL2402002 T3 PL 2402002T3
- Authority
- PL
- Poland
- Prior art keywords
- oxadiazole
- compositions
- stop codon
- diseases associated
- treating diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66978905P | 2005-04-08 | 2005-04-08 | |
US78739506P | 2006-03-30 | 2006-03-30 | |
EP11175569.0A EP2402002B1 (en) | 2005-04-08 | 2006-04-06 | Compositions comprising an 1,2,4-oxadiazole and uses thereof for treating diseases associated with a premature stop codon |
PCT/US2006/012887 WO2006110483A1 (en) | 2005-04-08 | 2006-04-06 | Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
EP06749439A EP1874306B1 (en) | 2005-04-08 | 2006-04-06 | Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2402002T3 true PL2402002T3 (pl) | 2018-11-30 |
Family
ID=36763092
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL11175569T PL2402002T3 (pl) | 2005-04-08 | 2006-04-06 | Kompozycje zawierające kwas 1,2,4-oksadiazolobenzoesowy i ich zastosowania do leczenia chorób związanych z przedwczesnym kodonem stop |
PL06749439T PL1874306T3 (pl) | 2005-04-08 | 2006-04-06 | Kompozycje zawierające 1,2,4-oksadiazol aktywny po podaniu doustnie w celu supresyjnego leczenia niesensownej mutacji |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL06749439T PL1874306T3 (pl) | 2005-04-08 | 2006-04-06 | Kompozycje zawierające 1,2,4-oksadiazol aktywny po podaniu doustnie w celu supresyjnego leczenia niesensownej mutacji |
Country Status (17)
Country | Link |
---|---|
US (7) | US8716321B2 (pl) |
EP (2) | EP2402002B1 (pl) |
JP (3) | JP5800451B2 (pl) |
CN (1) | CN103720688A (pl) |
AU (1) | AU2006235115C1 (pl) |
BR (1) | BRPI0609089A2 (pl) |
CA (1) | CA2603402C (pl) |
DK (2) | DK2402002T3 (pl) |
ES (2) | ES2390804T3 (pl) |
HK (1) | HK1111897A1 (pl) |
IL (2) | IL186433A (pl) |
MX (1) | MX2007012206A (pl) |
NO (2) | NO339909B1 (pl) |
NZ (1) | NZ562197A (pl) |
PL (2) | PL2402002T3 (pl) |
PT (2) | PT2402002T (pl) |
WO (1) | WO2006110483A1 (pl) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3345895T3 (pl) | 2003-04-11 | 2020-05-18 | Ptc Therapeutics, Inc. | Związek kwasu 1,2,4-oksadiazolobenzoesowego i jego zastosowanie do supresji mutacji nonsensownych i leczenia choroby |
PL2402002T3 (pl) | 2005-04-08 | 2018-11-30 | Ptc Therapeutics, Inc. | Kompozycje zawierające kwas 1,2,4-oksadiazolobenzoesowy i ich zastosowania do leczenia chorób związanych z przedwczesnym kodonem stop |
BRPI0710213A2 (pt) | 2006-03-30 | 2011-04-12 | Ptc Therapeutics Inc | métodos para produzir uma quantidade efetiva de uma proteìna de transleitura funcional codificada por uma sequência de ácido nucleico que compreende uma mutação não-sentido e para tratar, controlar e/ou prevenir uma doença |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
ES2882684T3 (es) | 2006-04-07 | 2021-12-02 | Vertex Pharma | Preparación de moduladores de transportadores del casete de unión a ATP |
ZA200901782B (en) | 2006-09-08 | 2010-06-30 | Ptc Therapeutics Inc | Processes for the preparation of 1, 2, 4-oxadiazole benzoic acids |
US8101641B2 (en) | 2006-09-25 | 2012-01-24 | Ptc Therapeutics, Inc. | Hydroxylated 1,2,4-oxadiazole benzoic acid compounds and compositions thereof |
SG185979A1 (en) * | 2006-09-25 | 2012-12-28 | Ptc Therapeutics Inc | Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
RS54025B1 (en) | 2006-10-12 | 2015-10-30 | Ptc Therapeutics Inc. | DOSAGE PROCEDURES FOR ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENS MUTATION SUPPRESSION THERAPY |
AU2016262645B2 (en) * | 2006-10-12 | 2018-05-17 | Ptc Therapeutics, Inc. | Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
MX2009012558A (es) | 2007-08-03 | 2010-04-21 | Biomarin Iga Ltd | Combinaciones de farmacos para el tratamiento de distrofia muscular de duchenne. |
GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
NZ598941A (en) | 2007-11-16 | 2013-06-28 | Vertex Pharma | Isoquinoline modulators of ATP-Binding Cassette transporters |
DK3170818T3 (da) | 2007-12-07 | 2020-04-14 | Vertex Pharma | Faste former af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre |
EP2980077B1 (en) | 2008-03-31 | 2020-05-06 | Vertex Pharmaceuticals Incorporated | Pyridyl derivatives as cftr modulators |
EP4253381A3 (en) | 2010-03-25 | 2023-11-01 | Vertex Pharmaceuticals Incorporated | Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]d ioxol-5-yl)-n-(1-(2,3-dihydroxyp ropyl)-6-fluoro-2-(1-hydroxy- 2-methylpropan-2-yl)-1h-indol- 5-yl) cyclopropanecarboxamide |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
RS54783B1 (sr) | 2010-04-07 | 2016-10-31 | Vertex Pharma | Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzoeve kiseline |
DK3150198T3 (da) | 2010-04-07 | 2021-11-01 | Vertex Pharma | Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf |
CN105130948A (zh) | 2010-04-22 | 2015-12-09 | 弗特克斯药品有限公司 | 制备环烷基甲酰胺基-吲哚化合物的方法 |
US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
CN103189060A (zh) * | 2010-08-05 | 2013-07-03 | 里尔法律与医疗卫生第二大学 | 用于对无义突变介导的疾病进行治疗的化合物和含有所述化合物的药物组合物 |
CA2808501A1 (en) | 2010-08-23 | 2012-03-01 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof |
US9254291B2 (en) | 2011-11-08 | 2016-02-09 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
ES2742277T3 (es) | 2012-01-25 | 2020-02-13 | Vertex Pharma | Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-ilo) ciclopropano carboxamido)-3metilpiridin-2-ilo)benzoico y su administración |
CA2878057A1 (en) | 2012-07-16 | 2014-01-23 | Rossitza Gueorguieva Alargova | Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
LT2914248T (lt) | 2012-11-02 | 2018-11-26 | Vertex Pharmaceuticals Incorporated | Farmacinės kompozicijos, skirtos cftr medijuotų ligų gydymui |
WO2014153643A1 (en) * | 2013-03-26 | 2014-10-02 | The University Of British Columbia | Compositions and methods for use thereof in the treatment of aniridia |
CA2942147C (en) * | 2014-03-06 | 2022-12-13 | Ptc Therapeutics, Inc. | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid |
RS57476B9 (sr) | 2014-04-15 | 2021-10-29 | Vertex Pharma | Farmaceutske kompozicije za lečenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze |
US20170196842A1 (en) * | 2014-06-06 | 2017-07-13 | Ptc Therapeutics, Inc. | Methods of treatment using a 1,2,4-oxadiazole benzoic acid |
WO2016057572A1 (en) | 2014-10-06 | 2016-04-14 | Mark Thomas Miller | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2017075312A1 (en) | 2015-10-30 | 2017-05-04 | Ptc Therapeutics, Inc. | Methods for treating epilepsy |
CA3048204A1 (en) | 2015-12-23 | 2017-06-29 | Moonshot Pharma Llc | Methods for inducing an immune response |
TW201808922A (zh) * | 2016-06-20 | 2018-03-16 | 台灣神隆股份有限公司 | 製備阿塔魯仁及其中間體的方法 |
WO2018050706A1 (en) * | 2016-09-13 | 2018-03-22 | Marco Cipolli | Method of treatment of shwachman-diamond syndrome |
WO2018237326A1 (en) | 2017-06-22 | 2018-12-27 | 1AlMOONSHOT PHARMA LLC | METHODS OF TREATING CANCER USING COMPOSITIONS COMPRISING AMLEXANOX AND IMMUNOMODULATORS |
ES2964964T3 (es) | 2017-11-01 | 2024-04-10 | Bristol Myers Squibb Co | Compuestos bicíclicos puenteados como moduladores del receptor X farnesoide |
WO2019101709A1 (en) | 2017-11-23 | 2019-05-31 | Universita' Degli Studi Di Palermo | Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations |
WO2020128816A2 (en) | 2018-12-20 | 2020-06-25 | Pfizer Inc. | Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent |
AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
JP2022519771A (ja) | 2019-02-15 | 2022-03-24 | ブリストル-マイヤーズ スクイブ カンパニー | ファルネソイドx受容体モジュレータとして有用な置換アミド化合物 |
JP7449300B2 (ja) | 2019-02-15 | 2024-03-13 | ブリストル-マイヤーズ スクイブ カンパニー | ファルネソイドx受容体モジュレータとして有用な置換アミド化合物 |
AU2020221370A1 (en) | 2019-02-15 | 2021-10-07 | Bristol-Myers Squibb Company | Substituted bicyclic compounds as farnesoid x receptor modulators |
WO2022112919A1 (en) | 2020-11-25 | 2022-06-02 | Pfizer Inc. | (aza)benzothiazolyl substituted pyrazole compounds |
KR102665711B1 (ko) | 2021-12-21 | 2024-05-14 | 재단법인 아산사회복지재단 | Ras 활성도를 이용한 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 Ras 활성 억제제를 포함하는 신경섬유종증 예방 또는 치료용 약학적 조성물 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY128323A (en) * | 1996-09-30 | 2007-01-31 | Otsuka Pharma Co Ltd | Thiazole derivatives for inhibition of cytokine production and of cell adhesion |
FI107732B (fi) * | 1998-03-18 | 2001-09-28 | Xyrofin Oy | Laktitolin kiteyttäminen, kiteinen laktitolituote ja sen käyttö |
US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
EP1406632A4 (en) * | 2001-06-08 | 2009-11-04 | Cytovia Inc | 3-ARYL-5-ARYL-1,2,4-OXADIAZOLES AND THEIR ANALOGUES, CASPASE ACTIVATORS AND INDUCERS OF APOPTOSIS, AND USES THEREOF |
MY151199A (en) * | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
TW200812986A (en) * | 2002-08-09 | 2008-03-16 | Nps Pharma Inc | New compounds |
US20040253307A1 (en) * | 2003-02-04 | 2004-12-16 | Brian Hague | Sugar-free oral transmucosal solid dosage forms and uses thereof |
GB0303503D0 (en) * | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
PL3345895T3 (pl) * | 2003-04-11 | 2020-05-18 | Ptc Therapeutics, Inc. | Związek kwasu 1,2,4-oksadiazolobenzoesowego i jego zastosowanie do supresji mutacji nonsensownych i leczenia choroby |
US20050075375A1 (en) * | 2003-05-14 | 2005-04-07 | Anadys Pharmaceuticals, Inc. | Heterocyclic compounds for treating hepatitis C virus |
PL2402002T3 (pl) | 2005-04-08 | 2018-11-30 | Ptc Therapeutics, Inc. | Kompozycje zawierające kwas 1,2,4-oksadiazolobenzoesowy i ich zastosowania do leczenia chorób związanych z przedwczesnym kodonem stop |
US20070010553A1 (en) * | 2005-07-01 | 2007-01-11 | Astrazeneca Ab | New use |
ZA200901782B (en) | 2006-09-08 | 2010-06-30 | Ptc Therapeutics Inc | Processes for the preparation of 1, 2, 4-oxadiazole benzoic acids |
SG185979A1 (en) * | 2006-09-25 | 2012-12-28 | Ptc Therapeutics Inc | Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
CA2942147C (en) | 2014-03-06 | 2022-12-13 | Ptc Therapeutics, Inc. | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid |
-
2006
- 2006-04-06 PL PL11175569T patent/PL2402002T3/pl unknown
- 2006-04-06 PL PL06749439T patent/PL1874306T3/pl unknown
- 2006-04-06 WO PCT/US2006/012887 patent/WO2006110483A1/en active Application Filing
- 2006-04-06 DK DK11175569.0T patent/DK2402002T3/en active
- 2006-04-06 ES ES06749439T patent/ES2390804T3/es active Active
- 2006-04-06 JP JP2008505534A patent/JP5800451B2/ja active Active
- 2006-04-06 CA CA2603402A patent/CA2603402C/en active Active
- 2006-04-06 ES ES11175569.0T patent/ES2683359T3/es active Active
- 2006-04-06 BR BRPI0609089-3A patent/BRPI0609089A2/pt not_active Application Discontinuation
- 2006-04-06 CN CN201310655012.3A patent/CN103720688A/zh active Pending
- 2006-04-06 PT PT11175569T patent/PT2402002T/pt unknown
- 2006-04-06 US US11/918,114 patent/US8716321B2/en active Active
- 2006-04-06 MX MX2007012206A patent/MX2007012206A/es active IP Right Grant
- 2006-04-06 EP EP11175569.0A patent/EP2402002B1/en active Active
- 2006-04-06 AU AU2006235115A patent/AU2006235115C1/en active Active
- 2006-04-06 NZ NZ562197A patent/NZ562197A/en unknown
- 2006-04-06 EP EP06749439A patent/EP1874306B1/en active Active
- 2006-04-06 DK DK06749439.3T patent/DK1874306T3/da active
- 2006-04-06 PT PT06749439T patent/PT1874306E/pt unknown
-
2007
- 2007-10-07 IL IL186433A patent/IL186433A/en active IP Right Grant
- 2007-11-07 NO NO20075682A patent/NO339909B1/no unknown
-
2008
- 2008-06-17 HK HK08106626.1A patent/HK1111897A1/xx unknown
-
2013
- 2013-06-04 JP JP2013117678A patent/JP5808367B2/ja active Active
-
2014
- 2014-03-21 US US14/221,352 patent/US9474743B2/en active Active
- 2014-12-30 IL IL236518A patent/IL236518B/en active IP Right Grant
-
2015
- 2015-07-06 JP JP2015134950A patent/JP2015212292A/ja active Pending
-
2016
- 2016-10-12 US US15/291,173 patent/US10034863B2/en active Active
-
2017
- 2017-01-09 NO NO20170035A patent/NO340617B1/no unknown
-
2018
- 2018-06-28 US US16/021,419 patent/US10285980B2/en active Active
-
2019
- 2019-03-29 US US16/368,992 patent/US10675272B2/en active Active
-
2020
- 2020-05-05 US US16/866,822 patent/US11497736B2/en active Active
-
2022
- 2022-10-11 US US17/963,838 patent/US20230218587A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2402002T (pt) | Composições de 1,2,4-oxadiazole oralmente activo para terapia de supressão de mutações nonsense | |
IL250858B (en) | A tetracycline compound, a pharmaceutical composition comprising the tetracycline compound, and the tetracycline compound or the pharmaceutical composition for treating a tetracycline responsive state | |
IL188602A0 (en) | Non-flammable insecticide composition and uses thereof | |
IL195580A (en) | L – fkbp polypeptides, preparations containing them, methods of preparation and use | |
EG25201A (en) | 4-cyclopropyl-1,2,3- thiadiazole compound, agrohorticultural plant disease controlling agent and method of using the same | |
TWI348354B (en) | 5,6-dialkyl-7-aminotriazolopyrimidines, their preparation and their use for controlling harmful fungi, and compositions comprising these compounds | |
IL190874A0 (en) | 1h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof | |
EP1874234A4 (en) | ARTIFICIAL HORN SKIN | |
PL1859004T3 (pl) | Środki sieciujące kompozycję opracowania odwiertu oraz ich zastosowania | |
PL1951838T3 (pl) | Kompozycje zawierające fluoroolefiny i ich zastosowania | |
AP2007004274A0 (en) | Immunogenic composition | |
ZA200802777B (en) | Safety needle with lockout mechanism | |
HK1128487A1 (en) | Compositions comprising fluoroolefins and uses thereof | |
ZA200901132B (en) | Human GLP-1 mimetibodies, compositions, methods and uses | |
SI1693027T1 (sl) | Konica za fakoemulsifikacijo | |
EP2103653A4 (en) | COMPOSITION AND LIGHT-EMITTING ELEMENT COMPRISING THE COMPOSITION | |
IL178166A0 (en) | 1,3,4-oxadiazol-2-ones as ppar delta | |
EP1828305A4 (en) | LOW LOSS PREIMPREGNE, COMPOSITIONS USEFUL FOR ITS PREPARATION AND USES THEREOF | |
EP1866044A4 (en) | COMPOSITION | |
IL184834A0 (en) | Compositions and methods for the manufacture thereof | |
ZA200802883B (en) | Antituberculous composition comprising oxazole compounds | |
LT1858481T (lt) | Oftalmologinės kompozicijos ir jų panaudojimas | |
IL205350A0 (en) | Novel 1, 3- dihydro - 5 - isobenzofurancarbonitrile derivatives and pharmacetical composition thereof for the treatment of premature ejaculation | |
ZA200903935B (en) | Novel arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use | |
EP1991059A4 (en) | INSECTICIDAL COMPOSITIONS AND USES THEREOF |